Ascentage Pharma Group International ADR(AAPG) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 16 at 8:11 AM ET (Korea 9/16 21:11)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.26 | Insider Own | - | Shs Outstand | 52.2M | Perf Week | -8.26% |
| Market Cap | 1.49B | Forward P/E | - | EPS next Y | 62.16% | Insider Trans | - | Shs Float | - | Perf Month | -15.79% |
| Enterprise Value | 1.52B | PEG | - | EPS next Q | -0.36 | Inst Own | 0.02% | Short Float | - | Perf Quarter | -7.73% |
| Income | -0.21B | P/S | 16.2 | EPS this Y | 43.57% | Inst Trans | 1.26% | Short Ratio | 1.42 | Perf Half Y | -34.72% |
| Sales | 0.09B | P/B | 18.14 | EPS next 5Y | 51.44% | ROA | -46.64% | Short Interest | 0.02M | Perf YTD | -39.02% |
| Book/sh | 0.88 | P/C | 5.32 | EPS past 3/5Y | 0.8% -1.32% | ROE | -240.66% | 52W High | -60.47% ($40.47) | Perf Year | -58.58% |
| Cash/sh | 3.01 | P/FCF | - | Sales past 3/5Y | 36.88% 113.42% | ROIC | -121.48% | 52W Low | -0.19% ($16.03) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -12.46% | Gross Margin | 83.18% | Volatility(W/M) | 0.97% 2.56% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 16.53 | Sales Y/Y TTM | 69.8% | Oper. Margin | -220% | ATR (14) | 0.65 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.18 | EPS Q/Q | - | Profit Margin | -229.27% | RSI (14) | 39.35 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.22 | Sales Q/Q | - | SMA20 | -6.71% ($17.15) | Beta | 0.11 | Target Price | $46.29 |
| Payout | - | Debt/Eq | 3.76 | Earnings | 2026/8/18 | SMA50 | -11.37% ($18.05) | Rel Volume | 0.4 | Prev Close | $16.41 |
| Employees | 767 | LT Debt/Eq | 1.11 | EPS/Sales Surpr. | -490.95% -16.37% | SMA200 | -29.58% ($22.72) | Avg Volume(3M) | 0.01M | Price | $16 |
| IPO | 2025/1/27 | Option/Short | No/Yes | Trades | 118 | Volume | 4,294 | Change | -2.5% |
Company
AAPG is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 This is a China-based biopharmaceutical company that develops and commercializes cancer therapeutics. Using technology that targets cell death pathways, the company develops treatments for blood cancers and other indications. Its operating model combines commercialized products in China with a global clinical pipeline and pharmaceutical partnerships. It has established itself as a differentiated oncology biotech with a cell death-targeting approach.
Over the past 1 year, on the lower side
60% below its 1-year high.
AAPG has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +43.6% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 0.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
ECNS 0.01%
EEMS 0.00%
CXSE 0.00%
VSS 0.00%
KAIT 0.00%It ranks #4 in the industry
Based on market cap of $1B.
AAPG $1B PER -
VRTX $130B PER 29.9
REGN $80B PER 19.1
ARGX $61B PER 37.3
FAQ
What kind of company is AAPG?
AAPG belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AAPG?
The market cap of AAPG is approximately $1.5B, ranking 2,337 within its sector.
What is the 52-week high and low for AAPG?
AAPG has recorded a 52-week high of $40.47 and a low of $16.03.
